Traditionally, the activation of microglia and astrocytes is assessed through Iba1/CD86 and glial fibrillary acidic protein (GFAP) immunostaining, respectively, consistently showing a positive correlation with the rate of disease progression in ALS patients [14]. Here, GFAP is linked to amyotrophic lateral sclerosis.